← Leaderboards
Mark R. Schleiss
University Of Minnesota
$10,248,102
Attributed
$14,611,307
Total exposure
11
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,611,307 · 11
By mechanism
R01$12,246,805 · 5
R21$1,221,411 · 3
T32$649,851 · 1
R56$342,000 · 1
R03$151,240 · 1
Top collaborators
- Adam P. Geballe11 shared
- Michael A Mcvoy11 shared
- Yuying Liang2 shared
- Meghan Rae Swanson1 shared
Most similar at University Of Minnesota
Same institution · by research overlap
- Alistair McGregor$8,487,942
- Benjamin J Perrin$4,377,982
- Yuying Liang$5,110,790
- Steven Sung Kyun Juhn$1,424,240
- Craig John Bierle$2,400,280
Others in their field
Top investigators on “Cytomegalovirus”
- Constance Ann Benson · University Of California, San Diego$154,530,762
- Curtis L Meinert · Johns Hopkins University$72,267,482
- Louis J. Picker · Oregon Health And Science University$67,787,971
- Robert Turner Schooley · University Of Colorado Denver$42,307,156
- Dan H. Barouch · Fred Hutchinson Cancer Center$34,316,808
- Jay A Nelson · Oregon Health & Science University$28,085,685
Research focus
CytomegalovirusCongenital InfectionVaccinesCaviaInfectionCytomegalovirus InfectionsVirusResponseProteinsAntibodiesAnimalsRecombinantsCytomegalovirus VaccinesImmuneImmune ResponseImmunityGuinea Pig CytomegalovirusClinical TrialsCytokineViralUnited StatesPublic Health PrioritiesCellsAnimal Model
Grant awards (47)
Neurodevelopmental Outcomes for CMV Infections Identified by Newborn Screening$676,561
R01 · FY2025 · HD
Optimizing Immunity and Maternal Host Defense Against Congenital Cytomegalovirus Infection$623,296
R01 · FY2023 · HD · contact PI
Viral Vectored COVID-19 Vaccines in a Guinea Pig Perinatal Infection Model$232,500
R21 · FY2023 · AI · contact PI
Optimizing Immunity and Maternal Host Defense Against Congenital Cytomegalovirus Infection$629,164
R01 · FY2022 · HD · contact PI
Viral Vectored COVID-19 Vaccines in a Guinea Pig Perinatal Infection Model$193,750
R21 · FY2022 · AI · contact PI
Optimizing Immunity and Maternal Host Defense Against Congenital Cytomegalovirus Infection$635,993
R01 · FY2021 · HD · contact PI
Optimizing Immunity and Maternal Host Defense Against Congenital Cytomegalovirus Infection$655,748
R01 · FY2020 · HD · contact PI
Optimizing Immunity and Maternal Host Defense Against Congenital Cytomegalovirus Infection$689,044
R01 · FY2019 · HD · contact PI
Optimized Vaccines Against Congenital Infection and Maternal Reinfection with CMV$319,135
R01 · FY2019 · HD · contact PI
Optimized Vaccines Against Congenital Infection and Maternal Reinfection with CMV$319,135
R01 · FY2018 · HD · contact PI
Optimized Vaccines Against Congenital Infection and Maternal Reinfection with CMV$322,870
R01 · FY2017 · HD · contact PI
Optimized Vaccines Against Congenital Infection and Maternal Reinfection with CMV$323,338
R01 · FY2016 · HD · contact PI
ELISPOT Peptide Mapping Assay to Identify Novel Candidate CMV Vaccine Antigens$75,240
R03 · FY2016 · HD · contact PI
Viral immunomodulation and rational CMV vaccine design$489,296
R01 · FY2015 · HD · contact PI
Preclinical Evaluation of a Novel rLCMV Single-Cycle Vectored CMV Vaccine$342,000
R56 · FY2015 · AI · contact PI
Optimized Vaccines Against Congenital Infection and Maternal Reinfection with CMV$339,605
R01 · FY2015 · HD · contact PI
Bedside-to-Bench Research Training for Pediatric Infectious Diseases Fellows$126,161
T32 · FY2015 · HD · contact PI
ELISPOT Peptide Mapping Assay to Identify Novel Candidate CMV Vaccine Antigens$76,000
R03 · FY2015 · HD · contact PI
Viral immunomodulation and rational CMV vaccine design$477,070
R01 · FY2014 · HD · contact PI
Bedside-to-Bench Research Training for Pediatric Infectious Diseases Fellows$122,844
T32 · FY2014 · HD · contact PI
Viral immunomodulation and rational CMV vaccine design$514,634
R01 · FY2013 · HD · contact PI
Bedside-to-Bench Research Training for Pediatric Infectious Diseases Fellows$129,733
T32 · FY2013 · HD · contact PI
Viral immunomodulation and rational CMV vaccine design$461,007
R01 · FY2012 · HD · contact PI
Bedside-to-Bench Research Training for Pediatric Infectious Diseases Fellows$138,453
T32 · FY2012 · HD · contact PI
Viral immunomodulation and rational CMV vaccine design$62,659
R01 · FY2012 · HD · contact PI
Viral immunomodulation and rational CMV vaccine design$479,788
R01 · FY2011 · HD · contact PI
Bedside-to-Bench Research Training for Pediatric Infectious Diseases Fellows$132,660
T32 · FY2011 · HD · contact PI
Vaccines for Prevention of Experimental Congenital CMV$252,706
R01 · FY2009 · HD · contact PI
Vaccines for Prevention of Experimental Congenital CMV$252,706
R01 · FY2008 · HD · contact PI
Viral Immunomodulation and Rational CMV Vaccine Design$372,032
R01 · FY2007 · HD · contact PI
Vaccines for Prevention of Experimental Congenital CMV$257,864
R01 · FY2007 · HD · contact PI
Transgenic Plant-Derived CMV Glycoprotein B Vaccine$217,747
R21 · FY2007 · AI · contact PI
Novel Strategy for Animal Model Testing of HCMV Vaccines$210,705
R21 · FY2007 · AI · contact PI
Viral Immunomodulation and Rational CMV Vaccine Design$371,980
R01 · FY2006 · HD · contact PI
Vaccines for Prevention of Experimental Congenital CMV$265,564
R01 · FY2006 · HD · contact PI
Transgenic Plant-Derived CMV Glycoprotein B Vaccine$186,875
R21 · FY2006 · AI · contact PI
Novel Strategy for Animal Model Testing of HCMV Vaccines$179,834
R21 · FY2006 · AI · contact PI
Viral Immunomodulation and Rational CMV Vaccine Design$438,607
R01 · FY2005 · HD
Vaccines for Prevention of Experimental Congenital CMV$317,133
R01 · FY2005 · HD
Viral Immunomodulation and Rational CMV Vaccine Design$228,647
R01 · FY2004 · HD
Viral Immunomodulation and Rational CMV Vaccine Design$198,240
R01 · FY2004 · HD
Viral Immunomodulation and Rational CMV Vaccine Design$51,405
R01 · FY2004 · HD
Viral Immunomodulation and Rational CMV Vaccine Design$369,339
R01 · FY2003 · HD
VACCINES FOR PREVENTION OF EXPERIMENTAL CONGENITAL CMV$225,382
R01 · FY2003 · HD
VACCINES FOR PREVENTION OF EXPERIMENTAL CONGENITAL CMV$218,820
R01 · FY2002 · HD
VACCINES FOR PREVENTION OF EXPERIMENTAL CONGENITAL CMV$212,445
R01 · FY2001 · HD
VACCINES FOR PREVENTION OF EXPERIMENTAL CONGENITAL CMV$195,592
R01 · FY2000 · HD